Lexington, Massachusetts, US (On-site)1 open job
Wave Life Sciences develops RNA medicines targeting the root cause of severe genetic diseases, with clinical programs in obesity, liver, neuromuscular, and neurodegenerative disorders.
Wave Life Sciences USA, Inc. is a clinical-stage genetic medicines company developing RNA medicines intended to address the root cause of severe genetic diseases and other serious disorders. Headquartered in Cambridge, Massachusetts, with international locations, the company works with scientists, clinical teams, patients, and families across a pipeline that spans rare and prevalent conditions. Its technical stack runs deep on the biology side: RNA editing, RNA splicing, RNA interference, antisense silencing, oligonucleotide chemistry, human genetics, and RNA biology.
At the center is the PRISM platform, an integrated approach that combines RNA editing, splicing, RNAi, and antisense silencing with oligonucleotide chemistry and insights from human genetics to design therapeutics aimed at disease biology at its source. The clinical pipeline includes WVE-007 (obesity), WVE-006 (alpha-1 antitrypsin deficiency), and WVE-008 (PNPLA3 I148M liver disease), plus programs targeting Duchenne muscular dystrophy and Huntington's disease.
For security practitioners, the relevant surface is the business itself: a research organization whose work spans proprietary nucleic acid chemistry, human genetics data, and multi-program clinical development, coordinated across US and international sites and with external clinical and scientific collaborators. The company operates in the biotechnology and pharmaceuticals verticals, with programs touching rare disease, metabolic and liver disease, neuromuscular disease, and neurodegenerative disease. Specific security team structure, tooling, and infrastructure are not disclosed here.
